Evidence‐based path to newborn screening for duchenne muscular dystrophy

Jerry R. Mendell(Nationwide Children's Hospital), Robert B. Weiss(University of Utah), Heather Lilly(Ohio Department of Health), Cindy Hamil(University of Utah), Natalie Street(Centers for Disease Control and Prevention), Brett Duval(University of Utah), Kelley Kneile(Nationwide Children's Hospital), Maha Mahmoud(University of Utah), Chelsea Rankin(Nationwide Children's Hospital), Julie Gastier‐Foster(Nationwide Children's Hospital), Nancy D. Leslie(University of Cincinnati), Diane M. Dunn(University of Utah), Alexander Aoyagi(University of Utah), Chris Shilling(Nationwide Children's Hospital), Ram Chandrasekar(Ohio Department of Health), Kandice Roush(Nationwide Children's Hospital), Roula Al‐Dahhak(Nationwide Children's Hospital), Lauren Bird(Nationwide Children's Hospital), Kevin M. Flanigan(Nationwide Children's Hospital)
Annals of Neurology
January 13, 2012
10.1002/ana.23528
Cited by 816

Related Papers

The neurofibromatosis type 1 gene encodes a protein related to GAP
|Cell|1990|1.1k
Eteplirsen for the treatment of Duchenne muscular dystrophy
|Annals of Neurology|2013|793
The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae
|Cell|1990|693
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655
Clinical trial in duchenne dystrophy. I. The design of the protocol
|Muscle & Nerve|1981|563